ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Xinyue Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0002-3299-0806; OpenAlex author ID A5100757874. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates. Co-author DOI 10.5582/bst.2025.01271 ↗
Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chao Wu · 2 shared papers, 2025–2026 · strength 0.54
- Paper Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates. DOI 10.5582/bst.2025.01271 ↗
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Weishuai Liu · 2 shared papers, 2025–2026 · strength 0.54
- Paper Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates. DOI 10.5582/bst.2025.01271 ↗
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Jihui Hao · 2 shared papers, 2025–2026 · strength 0.54
- Paper Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates. DOI 10.5582/bst.2025.01271 ↗
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Chongbiao Huang · 1 shared paper, 2025 · strength 0.18
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Shengnan Li · 1 shared paper, 2025 · strength 0.18
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Song Gao · 1 shared paper, 2025 · strength 0.18
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Yiping Zou · 1 shared paper, 2025 · strength 0.18
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Jun Yu · 1 shared paper, 2025 · strength 0.18
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Yongjie Xie · 1 shared paper, 2025 · strength 0.18
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Yukuan Feng · 1 shared paper, 2025 · strength 0.18
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗
Chao Yang · 1 shared paper, 2025 · strength 0.18
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.